Figure 4.

UA‐mediated decreases in MT1/2 and Ca3/7 viability were blunted by PPARα inhibitors. A, UA‐mediated decreases in MT1/2 viability were partially reversed by PPARα inhibitor GW6471 (IC₅₀ reversal calculated from average of five independent experiments n = 3/exp, representative experiment shown). B, UA‐mediated decreases in Ca3/7 viability were partially reversed by PPARα inhibitor GW6471 (IC₅₀ reversal calculated from average of six independent experiments n = 3/exp, representative experiment shown). C, UA‐mediated decreases in MT1/2 viability were partially reversed by PPARα inhibitor MK 886 (IC₅₀ reversal calculated from average of four independent experiments, n = 3/exp, representative experiment shown). D, UA‐mediated decreases in Ca3/7 viability were partially reversed by PPARα inhibitor MK886 (IC₅₀ reversal calculated from average of four independent experiments, n = 3/exp, representative experiment shown). For all experiments, *P < 0.05, ***P < 0.005, ****P < 0.001